FRANKLIN, Tenn. / Sep 17, 2025 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in a fireside chat at the Jefferies 2025 Healthcare Services Conference, September 29 - 30, 2025, in Nashville, Tennessee.
In connection with the conference, there will be an online webcast of the Company’s presentation available on the Company’s website starting at 8:35 a.m. Central Time / 9:35 a.m. Eastern Time on Monday, September 29, 2025.
The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of June 30, 2025, Acadia operated a network of 274 behavioral healthcare facilities with approximately 12,100 beds in 39 states and Puerto Rico. With approximately 25,000 employees serving more than 82,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
| Last Trade: | US$14.49 |
| Daily Change: | -0.21 -1.43 |
| Daily Volume: | 812,221 |
| Market Cap: | US$1.310B |
November 05, 2025 August 05, 2025 May 12, 2025 February 27, 2025 October 30, 2024 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load